Gilead acquires Arcellx for $7.8B to gain control of anito-cel, a CAR T-cell therapy for multiple myeloma, with FDA decision expected by Dec. 23, 2026.

Gilead Sciences agreed to acquire biotech company Arcellx for $115 per share in cash plus a $5 contingent value right per share, valuing the deal at $7.8 billion, with completion expected in the second quarter of 2026. The transaction, which includes Gilead’s existing stake, gives Gilead full control of anito-cel, an investigational CAR T-cell therapy for relapsed or refractory multiple myeloma, which the FDA is reviewing with a decision expected by December 23, 2026. The acquisition aims to strengthen Gilead’s oncology pipeline and accelerate development of next-generation cancer treatments.